4,230 Shares in Danaher Corporation $DHR Acquired by GEM Asset Management LLC

GEM Asset Management LLC acquired a new position in Danaher Corporation (NYSE:DHR) in the 3rd quarter, HoldingsChannel reports. The firm acquired 4,230 shares of the conglomerate’s stock, valued at approximately $937,000.

A number of other large investors also recently modified their holdings of DHR. Copeland Capital Management LLC bought a new position in Danaher during the 3rd quarter valued at $773,000. Foster Group Inc. bought a new stake in shares of Danaher in the 3rd quarter worth $716,000. B. Riley Wealth Advisors Inc. bought a new stake in shares of Danaher in the 3rd quarter worth $3,054,000. Krilogy Financial LLC raised its holdings in shares of Danaher by 104.2% in the third quarter. Krilogy Financial LLC now owns 23,336 shares of the conglomerate’s stock valued at $5,170,000 after purchasing an additional 11,906 shares during the last quarter. Finally, Mechanics Bank Trust Department raised its holdings in shares of Danaher by 188.0% in the third quarter. Mechanics Bank Trust Department now owns 27,995 shares of the conglomerate’s stock valued at $6,202,000 after purchasing an additional 18,273 shares during the last quarter. Institutional investors own 79.05% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently commented on DHR. Weiss Ratings upgraded Danaher from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, September 16th. TD Cowen raised their target price on Danaher from $236.00 to $255.00 and gave the company a “buy” rating in a research report on Tuesday. UBS Group started coverage on shares of Danaher in a report on Wednesday, September 9th. They issued a “buy” rating and a $250.00 price target on the stock. Barclays increased their price target on shares of Danaher from $230.00 to $255.00 and gave the company an “overweight” rating in a research report on Wednesday, October 7th. Finally, Royal Bank Of Canada lifted their price objective on shares of Danaher from $215.00 to $250.00 and gave the stock an “outperform” rating in a research report on Monday, October 5th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, Danaher presently has an average rating of “Moderate Buy” and a consensus target price of $235.41.

Danaher Stock Performance

Shares of DHR opened at $223.30 on Wednesday. The firm has a market cap of $156.98 billion, a PE ratio of 39.66, a PEG ratio of 2.78 and a beta of 0.76. The stock’s fifty day moving average price is $212.41 and its two-hundred day moving average price is $195.13. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.65 and a quick ratio of 1.25. Danaher Corporation has a 1 year low of $160.93 and a 1 year high of $242.80.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Monday, July 20th. The conglomerate reported $1.94 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.85 by $0.09. The business had revenue of $6.26 billion for the quarter, compared to analysts’ expectations of $6.12 billion. Danaher had a return on equity of 11.04% and a net margin of 15.95%. The firm’s quarterly revenue was up 5.5% compared to the same quarter last year. During the same period in the previous year, the business posted $0.77 EPS. On average, equities research analysts forecast that Danaher Corporation will post 8.53 EPS for the current year.

Danaher Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be issued a dividend of $0.40 per share. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $1.60 dividend on an annualized basis and a yield of 0.7%. Danaher’s dividend payout ratio is 28.42%.

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.